Clinton Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Clinton Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-14,018	Closed	-$1.89M	–	425
2017 Q4	$1.89M	Buy	+14,018	New	+$1.94M	0.17%	182
2016 Q4	–	Sell	-12,252	Closed	-$1.49M	–	894
2016 Q3	$1.49M	Buy	+12,252	New	+$1.65M	0.07%	356
2016 Q2	–	Sell	-11,481	Closed	-$1.5M	–	960
2016 Q1	$1.5M	Sell	11,481 -2,278	-17%	-$284K	0.09%	326
2015 Q4	$1.93M	Sell	13,759 -10,287	-43%	-$1.43M	0.16%	205
2015 Q3	$3.19M	Buy	+24,046	New	+$4.14M	0.3%	98
2015 Q1	–	Sell	-1,644	Closed	-$269K	–	545
2014 Q4	$269K	Buy	+1,644	New	+$273K	0.08%	362

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Clinton Group's JAZZ Position: Q1 2018 in Review

Clinton Group sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2018, closing a stake of 14,018 shares — an estimated $1.89M sold.

Clinton Group first reported a position in JAZZ in Q4 2014 and held it in 6 quarters. The position peaked at $3.19M in Q3 2015. 323 funds tracked by Wall St. Rank hold JAZZ as of Q1 2018.

Clinton Group reported no remaining Jazz Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Clinton Group sold 14,018 Jazz Pharmaceuticals shares in Q1 2018, an estimated $1.89M.
Clinton Group first reported a position in Jazz Pharmaceuticals in Q4 2014 and held it in 6 quarters.
Clinton Group's Jazz Pharmaceuticals position peaked at $3.19M in Q3 2015.
323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2018.

Based on Clinton Group's 13F filing for Q1 2018, filed 14 May 2018.